pI: 4.053 |
Length (AA): 107 |
MW (Da): 11666 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 7 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
2 | 107 | 1onl (A) | 18 | 125 | 42.00 | 0 | 1 | 1.42 | -0.6 |
2 | 107 | 1htp () | 18 | 125 | 46.00 | 0 | 1 | 1.48 | -0.69 |
2 | 107 | 1zko (A) | 15 | 122 | 47.00 | 0 | 1 | 1.49 | -0.64 |
2 | 107 | 1hpc (A) | 18 | 125 | 46.00 | 0 | 1 | 1.65255 | -1.18 |
2 | 107 | 3a7l (A) | 19 | 126 | 46.00 | 0 | 1 | 1.64635 | -1.14 |
3 | 107 | 2edg (A) | 20 | 126 | 52.00 | 0 | 1 | 1.66721 | -0.82 |
4 | 107 | 1onl (A) | 20 | 125 | 43.00 | 0 | 1 | 1.58446 | -1.2 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | amastigotes, metacyclic. | Fernandes MC |
Fernandes MC | Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. |
Ortholog group members (OG5_127169)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G32470 | probable glycine cleavage system H protein 2 |
Arabidopsis thaliana | AT2G35120 | glycine cleavage system H protein 2 |
Arabidopsis thaliana | AT2G35370 | glycine decarboxylase complex protein H |
Brugia malayi | Bm1_19690 | glycine cleavage system H protein |
Candida albicans | CaO19.12473 | H-protein subunit of glycine cleavage system |
Candida albicans | CaO19.5006 | H-protein subunit of glycine cleavage system |
Caenorhabditis elegans | CELE_D1025.2 | Protein GCSH-1 |
Caenorhabditis elegans | CELE_F52A8.5 | Protein F52A8.5 |
Chlamydia trachomatis | CT_282 | glycine cleavage system protein H |
Dictyostelium discoideum | DDB_G0287791 | glycine cleavage system H-protein |
Dictyostelium discoideum | DDB_G0290845 | glycine cleavage system H-protein |
Dictyostelium discoideum | DDB_G0287773 | glycine cleavage system H-protein |
Drosophila melanogaster | Dmel_CG7758 | pumpless |
Escherichia coli | b2904 | glycine cleavage complex lipoylprotein |
Echinococcus granulosus | EgrG_000694900 | glycine cleavage system H protein |
Echinococcus multilocularis | EmuJ_000694900 | glycine cleavage system H protein |
Homo sapiens | 101060817 | glycine cleavage system H protein, mitochondrial-like |
Homo sapiens | ENSG00000140905 | glycine cleavage system protein H (aminomethyl carrier) |
Leishmania braziliensis | LbrM.34.4690 | glycine cleavage system H protein, putative |
Leishmania donovani | LdBPK_354790.1 | glycine cleavage system H protein, putative |
Leishmania infantum | LinJ.35.4790 | lipoic acid containing carrier protein, putative |
Leishmania major | LmjF.35.4720 | lipoic acid containing carrier protein, putative;with=GeneDB:LinJ35_V3.4790 |
Leishmania mexicana | LmxM.34.4720 | glycine cleavage system H protein, putative |
Loa Loa (eye worm) | LOAG_10305 | glycine cleavage system H protein |
Mycobacterium leprae | ML2077c | PROBABLE GLYCINE CLEAVAGE SYSTEM H PROTEIN GCVH |
Mus musculus | ENSMUSG00000034424 | glycine cleavage system protein H (aminomethyl carrier) |
Mus musculus | 102641654 | glycine cleavage system H protein, mitochondrial-like |
Mycobacterium tuberculosis | Rv1826 | Probable glycine cleavage system H protein GcvH |
Mycobacterium ulcerans | MUL_3045 | glycine cleavage system protein H |
Mycobacterium ulcerans | MUL_4903 | glycine cleavage system H protein GcvH |
Neospora caninum | NCLIV_021960 | Glycine cleavage system H protein, mitochondrial (Precursor), related |
Oryza sativa | 4349114 | Os10g0516100 |
Oryza sativa | 9269154 | Os02g0169700 |
Oryza sativa | 4328441 | Os02g0170100 |
Oryza sativa | 4341790 | Os06g0667600 |
Onchocerca volvulus | OVOC11752 | Glycine cleavage system H protein, mitochondrial homolog |
Plasmodium berghei | PBANKA_0915500 | glycine cleavage system H protein, putative |
Plasmodium falciparum | PF3D7_1132900 | glycine cleavage system H protein |
Plasmodium knowlesi | PKNH_0931100 | glycine cleavage system H protein, putative |
Plasmodium vivax | PVX_092250 | glycine cleavage system H protein, putative |
Plasmodium yoelii | PY05949 | probable glycine cleavage system h protein |
Saccharomyces cerevisiae | YAL044C | glycine decarboxylase subunit H |
Schistosoma japonicum | Sjp_0066200 | ko:K02437 glycine cleavage system H protein, putative |
Schmidtea mediterranea | mk4.027782.01 | Glycine cleavage system H protein, mitochondrial |
Schmidtea mediterranea | mk4.018963.03 | Glycine cleavage system H protein, mitochondrial |
Trypanosoma brucei gambiense | Tbg972.9.5660 | glycine cleavage system H protein, putative |
Trypanosoma brucei | Tb927.9.9840 | lipoic acid containing carrier protein, putative |
Trypanosoma cruzi | TcCLB.508457.30 | lipoic acid containing carrier protein, putative |
Trypanosoma cruzi | TcCLB.506885.430 | lipoic acid containing carrier protein, putative |
Toxoplasma gondii | TGME49_202960 | glycine cleavage H-protein |
Trichomonas vaginalis | TVAG_177600 | glycine cleavage system H protein, putative |
Trichomonas vaginalis | TVAG_100550 | glycine cleavage system H protein, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb09.211.1380 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb09.211.1380 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb09.211.1380 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb09.211.1380 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
b2904 | Escherichia coli | non-essential | goodall |
CELE_F52A8.5 | Caenorhabditis elegans | embryonic lethal | wormbase |
PBANKA_0915500 | Plasmodium berghei | Essential | plasmo |
TGME49_202960 | Toxoplasma gondii | Probably essential | sidik |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.2